about
SDHD promoter mutations are rare events in cutaneous melanomas but SDHD protein expression is downregulated in advanced cutaneous melanomaTERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomasTERT promoter mutations in pancreatic endocrine tumours are rare and mainly found in tumours from patients with hereditary syndromesOsteopontin-a splice variant is overexpressed in papillary thyroid carcinoma and modulates invasive behavior.The prognostic impact of TERT promoter mutations in glioblastomas is modified by the rs2853669 single nucleotide polymorphism.Etiopathogenesis of oncocytomas.TERT promoter mutations: a genetic signature of benign and malignant thyroid tumours occurring in the context of tinea capitis irradiation.pmTOR is a marker of aggressiveness in papillary thyroid carcinomas.Mitochondrial D310 D-Loop instability and histological subtypes in radiation-induced cutaneous basal cell carcinomas.TERT promoter mutations in skin cancer: the effects of sun exposure and X-irradiation.NIS expression in thyroid tumors, relation with prognosis clinicopathological and molecular features.Inhibitory Effects of Antagonists of Growth Hormone-Releasing Hormone (GHRH) in Thyroid Cancer.TERT, BRAF, and NRAS in Primary Thyroid Cancer and Metastatic Disease.Telomerase and N-Cadherin Differential Importance in Adrenocortical Cancers and Adenomas.Multinodular Goiter Progression Toward Malignancy in a Case of DICER1 Syndrome: Histologic and Molecular Alterations.mTOR Pathway in Papillary Thyroid Carcinoma: Different Contributions of mTORC1 and mTORC2 Complexes for Tumor Behavior and SLC5A5 mRNA Expression.mTOR activation in medullary thyroid carcinoma with RAS mutation.Loss of Mitochondrial SDHB Expression: What is its Role in Diffuse Thyroid Lipomatosis?TERT promoter mutations are associated with poor prognosis in cutaneous squamous cell carcinomaValidation of a Novel, Sensitive, and Specific Urine-Based Test for Recurrence Surveillance of Patients With Non-Muscle-Invasive Bladder Cancer in a Comprehensive Multicenter StudyBiomarkers for Bladder Cancer Diagnosis and Surveillance: A Comprehensive Review
P50
Q33853615-77A58FB2-7F29-472C-A9EC-4C3C58BD2A2BQ34313648-D9AFFBBF-566F-45A7-9127-E2F468800173Q37093384-D4250746-189A-40F4-8117-61D06FE42B5BQ37588399-C9EB4FE6-609E-4AD1-92BA-3033CF8BB9F0Q38903424-C2C42CA2-E00B-4930-8ACB-42041FA45572Q39421661-C8B47D33-9789-465E-985F-8161C69FA9F5Q40497799-EC1120E5-35D7-441D-B1DE-7A0B62573E03Q40602311-3DE706A7-3B93-4C8B-BE07-64308BA4FFDBQ42445888-EBAD0FFB-72FB-444E-B709-1FDF9EAEA38BQ42456732-3199A432-0367-429D-903E-C1FE505AB297Q47212889-045BDF11-C1EA-4710-B9EB-02330FACF666Q47765421-325332CB-0407-429D-A76A-9EB9D62B4617Q51092203-36432949-F5D1-4940-918B-D48A4922F95FQ51304058-64CA0520-16B2-4F82-B850-6D09D5EF2250Q52655919-DA4701E8-9539-44B6-8197-CB6B9CAA960BQ53682892-CFB83C80-4F22-4A19-8514-A82D05110DA5Q55071575-5C15D6CA-C2F8-4080-963B-F4F92B0F712BQ59600671-14AA1B5F-E874-4DEB-9C29-6FC4615D709BQ91232481-3445CD7C-6022-4974-8F96-F5D4649EAB88Q92539491-31C65CFB-E852-456D-8ECE-D02A69DE9A2AQ92663356-3FFCE08D-5F51-48F9-8170-E7EA97EB36EB
P50
description
onderzoeker
@nl
researcher ORCID ID = 0000-0002-6512-5328
@en
name
Rui Batista
@ast
Rui Batista
@en
Rui Batista
@es
Rui Batista
@nl
type
label
Rui Batista
@ast
Rui Batista
@en
Rui Batista
@es
Rui Batista
@nl
prefLabel
Rui Batista
@ast
Rui Batista
@en
Rui Batista
@es
Rui Batista
@nl
P106
P1153
55862177000
P31
P496
0000-0002-6512-5328